EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases

Kenta Nakamura, Toshihiro Shiozawa, Hiroaki Tachi, Jun Kanazawa, Takeshi Numata, Tomohiro Tamura, Shigen Hayashi, Tomoyuki Ogata, Kunihiko Miyazaki, Norihiro Kikuchi, Koichi Kurishima, Hiroaki Satoh und 1 weitere

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2026.101249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Kenta Nakamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan. Hauptthemen laut MEDLINE: Brain Neoplasms, Etoposide, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The management of brain metastases remains a major challenge in extensive-disease small-cell lung cancer (ED-SCLC). Although immune checkpoint inhibitor (ICI) therapy combined with etoposide and platinum (EP) is the standard treatment for ED-SCLC, its intracranial efficacy remains unclear. This study evaluated the efficacy of combined ICI and EP therapy, with a focus on intracranial response. METHODS: We retrospectively included 59 patients with ED-SCLC and brain metastases who received combined ICI and EP therapy. Efficacy endpoints included objective response rates (ORRs), progression-free survival (PFS), and overall survival (OS). The ORR and PFS were evaluated separately for intracranial (i) and extracranial (e) lesions. We also evaluated survival according to upfront brain radiotherapy (BRT) use prior to systemic chemotherapy. RESULTS: Patients with a performance status of 2 or 3 accounted for 27 % of the cohort. Nineteen patients (32 %) had symptomatic brain metastases. The iORR and eORR were 73 % and 78 %, respectively (p = 0.42). The median iPFS was 6.3 months (95 % confidence intervals [CI]: 4.5-8.0), comparable to the median ePFS of 5.2 months (95 % CI: 4.0-6.4). In survival analyses by upfront BRT, the median iPFS was numerically longer in the BRT group than in the non-BRT group (9.7 vs. 5.7 months, p = 0.09). The median OS did not differ significantly between the BRT and non-BRT groups (11.6 months vs. 10.9 months; p = 0.26). CONCLUSION: Combined ICI and EP therapy demonstrated favorable intracranial efficacy. OS was similar regardless of upfront BRT, supporting this regimen as a valuable treatment option for ED-SCLC with brain metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsEtoposideSmall Cell Lung CarcinomaLung NeoplasmsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedPlatinumAdult

Stichwörter der Autor:innen

Brain metastasisImmune checkpoint inhibitorsIntracranial efficacyRadiotherapySmall-cell lung cancer

Substanzen

EtoposideImmune Checkpoint InhibitorsPlatinum

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
  • Department of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. Electronic address: t-shiozawa@md.tsukuba.ac.jp.
  • Divisions of Respiratory Medicine, Hitachi General Hospital, Hitachi, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Tokai, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
  • Respiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.

Zitieren

APA

Nakamura, K., Shiozawa, T., Tachi, H., Kanazawa, J., Numata, T., Tamura, T., Hayashi, S., Ogata, T., Miyazaki, K., Kikuchi, N., Kurishima, K., Satoh, H., & Hizawa, N. (2026). Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101249

Vancouver

Nakamura K, Shiozawa T, Tachi H, Kanazawa J, Numata T, Tamura T, et al. Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101249

BibTeX
@article{Nakamura2026,
  author = {Nakamura, Kenta and Shiozawa, Toshihiro and Tachi, Hiroaki and Kanazawa, Jun and Numata, Takeshi and Tamura, Tomohiro and Hayashi, Shigen and Ogata, Tomoyuki and Miyazaki, Kunihiko and Kikuchi, Norihiro and Kurishima, Koichi and Satoh, Hiroaki and Hizawa, Nobuyuki},
  title = {Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2026.101249}
}
Kostenlos starten →